Adaptimmune Therapeutics PLC – (NASDAQ:ADAP)’s share price traded down 6.6% during trading on Thursday . The company traded as low as $1.08 and last traded at $1.14, 518,218 shares traded hands during trading. An increase of 66% from the average session volume of 311,967 shares. The stock had previously closed at $1.22.
Several research analysts recently weighed in on the stock. ValuEngine raised shares of Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday. Cowen reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics in a research note on Thursday, November 7th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. Adaptimmune Therapeutics has an average rating of “Hold” and a consensus price target of $6.59.
The business has a 50 day simple moving average of $0.94 and a two-hundred day simple moving average of $2.20. The company has a current ratio of 3.93, a quick ratio of 3.93 and a debt-to-equity ratio of 0.15. The company has a market cap of $119.35 million, a PE ratio of -1.19 and a beta of 1.82.
A number of institutional investors and hedge funds have recently bought and sold shares of ADAP. Baillie Gifford & Co. grew its holdings in Adaptimmune Therapeutics by 7.9% in the second quarter. Baillie Gifford & Co. now owns 4,143,840 shares of the biotechnology company’s stock valued at $16,658,000 after purchasing an additional 304,650 shares during the period. Aperio Group LLC acquired a new position in Adaptimmune Therapeutics in the second quarter valued at $88,000. Man Group plc boosted its holdings in Adaptimmune Therapeutics by 37.4% in the second quarter. Man Group plc now owns 1,839,225 shares of the biotechnology company’s stock valued at $7,394,000 after acquiring an additional 500,595 shares during the last quarter. Acadian Asset Management LLC grew its position in Adaptimmune Therapeutics by 119.5% during the second quarter. Acadian Asset Management LLC now owns 42,517 shares of the biotechnology company’s stock valued at $170,000 after acquiring an additional 23,143 shares during the period. Finally, Rock Springs Capital Management LP grew its position in Adaptimmune Therapeutics by 9.4% during the second quarter. Rock Springs Capital Management LP now owns 875,000 shares of the biotechnology company’s stock valued at $3,518,000 after acquiring an additional 75,000 shares during the period. Institutional investors own 65.06% of the company’s stock.
Adaptimmune Therapeutics Company Profile (NASDAQ:ADAP)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
Featured Article: Earnings Per Share
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.